|
| Press Releases |
|
 |
|
| Saturday, April 29, 2017 |
|
|
Nanobiotix: 2016 Annual Results |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2016. more info >> |
|
| Tuesday, April 4, 2017 |
|
|
Nanobiotix Expands Its Clinical Development in Head and Neck Cancer and Immuno-Oncology |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the expansion and acceleration of its clinical development activities. more info >> |
|
| Friday, March 24, 2017 |
|
|
NANOBIOTIX: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that the Independent Data Monitoring Committee (IDMC) has completed the interim evaluation of the Phase II/III trial results (Act.In.Sarc) of NBTXR3 in soft tissue sarcoma. more info >> |
|
| Tuesday, March 7, 2017 |
|
|
Nanobiotix to Present Preclinical Data on Nanoparticle Radioenhancer NBTXR3 at the AACR Annual Meeting 2017 |
| NANOBIOTIX today announced the presentation of NBTXR3 preclinical studies demonstrating 1) the antitumor efficacy of NBTXR3 in five different in vivo human cancer models and 2) the antitumor efficacy of NBTXR3 in combination with chemotherapy, in both in vitro and in vivo studies. more info >> |
|
| Tuesday, February 7, 2017 |
|
|
Nanobiotix Appoints Senior Executive from Pharmaceutical Industry, as Chief Operating Officer |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today the appointment of Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer (COO). more info >> |
|
| Wednesday, February 1, 2017 |
|
|
NANOBIOTIX: 2016 Review and 2017 Anticipated Milestones |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides its activities and achievements during 2016 and an overview of anticipated 2017 milestones. more info >> |
|
| Thursday, December 15, 2016 |
|
|
Nanobiotix Reports Positive Phase I/II Preliminary Data on Feasibility and Safety of NBTXR3 in Liver Cancers Trial |
| NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces a positive readout of initial data on the safety and feasibility from the first patients treated in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and metastatic tumors. more info >> |
|
| Tuesday, November 29, 2016 |
|
|
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3 |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides an update on the global development of its lead product, NBTXR3, across all indications. more info >> |
|
| Monday, November 14, 2016 |
|
|
Nanobiotix Presents NBTXR3 Preclinical Data Demonstrating Its Potential Usage as In Situ Vaccine for Cancer at the Society for Immunotherapy of Cancer Annual Meeting |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces preclinical data demonstrating that its leading radioenhancer nanoparticle, NBTXR3, actively stimulates the host immune system to attack tumor cells. more info >> |
|
| Monday, November 7, 2016 |
|
|
Nanobiotix' Partner PharmaEngine Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia |
| NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205) today announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October. The trial is evaluating the optimal dose, safety and preliminary efficacy of Nanobiotix's lead product. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
エーザイ、「SX 銘柄 2026」に初選定
May 18, 2026 14:50: JST
|
|
|
MHIEC、「流動床式ガス化改質システム」の廃棄物処理技術検証結果書を日本環境衛生センターから取得
May 18, 2026 14:50: JST
|
|
|
Paying Off Debt but Still Want to Save? Here's How to Manage Both
May 18, 2026 14:00 HKT/SGT
|
|
|
S CUBE Capital Announces Strategic Acquisition by InCred Capital to enhance Global Asset Management Capabilities
May 18, 2026 12:30 HKT/SGT
|
|
|
三菱重工、長崎海運人材育成協会向けCTVのウォータージェット推進装置を受注
May 18, 2026 12:20: JST
|
|
|
三菱重工サーマルシステムズ、伊「A'デザインアワード2026」を受賞
May 18, 2026 12:15: JST
|
|
|
Your Go-To Travel Checklist for Smarter, Reward-Focused Travel Planning
May 18, 2026 11:12 HKT/SGT
|
|
|
JCB and Wonder Advance Cashless Taxi Payments in Hong Kong
May 18, 2026 10:00 JST
|
|
|
「星樞計劃」正式發布 鈞達股份多家下屬公司成為上海太空算力產業生態夥伴發起及首批單位
May 17, 2026 12:51 HKT/SGT
|
|
|
Shoucheng Holdings' First-Quarter Report Shows 18% Core Profit Growth and Sustained High Shareholder Returns
May 16, 2026 08:49 HKT/SGT
|
|
|
首程控股一季報核心利潤增長18% 高股東回報持續兌現
May 16, 2026 08:49 HKT/SGT
|
|
|
Tabor Redefines Anti-Drone Testing with Software-Defined SDR Platform
May 16, 2026 07:00 HKT/SGT
|
|
|
NEC completes construction of approximately 2,250 km EMCS submarine cable linking Pacific island nations
May 15, 2026 17:36 JST
|
|
|
Fujitsu and Science Tokyo launch joint research hub for quantum hardware advancement and talent development
May 15, 2026 17:12 JST
|
|
|
Fujitsu and IBM Japan formalize collaboration in healthcare sector
May 15, 2026 16:42 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
